Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Apatinib + Sintilimab + SOX in Gastric Cancer
NCT06925243Phase 3Recruiting
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Rivoceranib in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms). Primary endpoint: Pathological Complete Response Rate at 4 months. Started Apr 2025; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06925243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06925243.